[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-369954-105":59,"doc-detail-369954-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","herthena-pantumor01-clinical-trial-protocol-phase-ii-study-of-patritumab-deruxtecan-her3-dxd","HERTHENA-PanTumor01 - Clinical trial protocol - phase II study of patritumab deruxtecan (HER3-DXd)","","HER3 is a receptor tyrosine kinase expressed across many solid tumors, and higher HER3 levels correlate with poorer outcomes. No HER3-directed antibody-drug conjugate is currently approved, creating a need for effective options for patients progressing after standard therapies. HER3-DXd is an investigational HER3-targeted ADC using an anti-HER3 monoclonal antibody linked via a cleavable tetrapeptide-based linker to a topoisomerase I inhibitor payload. The study evaluates efficacy and safety in relapsed or refractory locally advanced/metastatic solid tumors.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/herthena-pantumor01-clinical-trial-protocol-phase-ii-study-of-patritumab-deruxtecan-her3-dxd/369954/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/herthena-pantumor01-clinical-trial-protocol-phase-ii-study-of-patritumab-deruxtecan-her3-dxd/369954.png","ImageObject",300,407,{"name":92,"@type":93},"Guten tag","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-12","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":39},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What is HER3-DXd and what is its mechanism of action?","Question",{"text":112,"@type":113},"HER3-DXd is an investigational antibody-drug conjugate. It uses an anti-HER3 monoclonal antibody linked to a topoisomerase I inhibitor payload via a cleavable linker, releasing chemotherapy inside HER3-expressing cancer cells.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"What patient populations and cancer types are included in HERTHENA-PanTumor01?",{"text":117,"@type":113},"The trial enrolls patients with relapsed or refractory locally advanced or metastatic solid tumors that are unresectable. Tumor types include melanoma, head and neck squamous cell carcinoma, gastric/gastroesophageal junction, ovarian, cervical, endometrial, bladder, esophageal squamous cell, pancreatic, and prostate cancers.",{"name":119,"@type":110,"acceptedAnswer":120},"How is HERTHENA-PanTumor01 administered and what are the primary goals?",{"text":121,"@type":113},"Participants receive HER3-DXd every 3 weeks via IV infusion. The study aims to assess how well HER3-DXd shrinks tumors and to characterize side effects during treatment.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},369954,1790648543,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":39,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":52,"language":139,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":67,"update_tm":143,"read_time":144,"preview_page_count":19,"preview_urls":145},687212321768,"https://ap-avatar.wpscdn.com/avatar/a0010bdbe886d2fe77?x-image-process=image/resize,m_fixed,w_180,h_180&k=1789897067658708522","FUTURE ONCOLOGY  \n2025, VOL. 21, NO. 25, 3283–3292  \n[https://doi.org/10.1080/14796694.2025.2561539](https://doi.org/10.1080/14796694.2025.2561539)  \nCLINICAL TRIAL PROTOCOL  \nHERTHENA-PanTumor01: a phase II study of patritumab deruxtecan (HER3-DXd) in previously treated advanced solid tumors  \nThomas Powles a*, Aarti Bhatia b*, Barbara Burtness b, Takahiro Kogawa c, Tomohiro Nishina d,  \nIzuma Nakayama e, Christos Fountzilas f, Dani R. Castillo g, Meredith McKean h, Funda Meric-Bernstam i, Nicoletta Colomboj, James W. Smithy k, Jérome Fayette l, Sunandana Chandra m, David W. Sternbergn, Fan Jin o, Kendall Sullivanp, Sue Yuehq, Graham Clinthorne r, Ariel E. Aguilo s, Ragini Kudchadkarq and Hidetoshi Hayashi t*  \naGenitourinary Oncology, Bart’s Cancer Institute, Queen Mary University of London, London, UK; bMedical Oncology, Yale School of Medicine, Yale Cancer Center, New Haven, CT, USA; cEarly Clinical Development for Cancer, The Cancer Institute Hospital of JFCR, Tokyo, Japan; dGastrointestinal Medical Oncology, National Hospital Organization Shikoku Cancer Center, Matsuyama, Ehime, Japan; eGastrointestinal Oncology, National Cancer Center Hospital East, Kashiwa, Japan; fMedicine, Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA; gMedical Oncology, City of Hope Comprehensive Cancer Center, Duarte, CA, USA; hMelanoma and Skin Cancer Research, Sarah Cannon Research Institute, Nashville, TN, USA; iInvestigational Cancer Therapeutics, The University ofTexas MD Anderson Cancer Center, Houston, TX, USA; jGynecologic Oncology, Università degli Studi di Milano-Bicocca, IEO – Istituto Europeo di Oncologia, Milan, Italy; kMedicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA; lMedical Oncology, Centre Léon Bérard, Lyon, France; mHematology/Oncology, Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago, IL, USA; nOncology Clinical Development, Daiichi Sankyo, Inc., Basking Ridge, NJ, USA; oClinical, Merck & Co., Inc., North Wales, PA, USA; pClinical, Daiichi Sankyo, Inc., Basking Ridge, NJ, USA; qDaiichi Sankyo, Inc., Basking Ridge, NJ, USA; rPantumor, Medical Affairs, Daiichi Sankyo, Inc., Basking Ridge, NJ, USA; sOncology R&D, Daiichi Sankyo, Inc., Basking Ridge, NJ, USA; tMedical Oncology, Kindai University, Osaka-Sayama, Osaka, Japan  \nABSTRACT  \nHuman epidermal growth factor receptor 3 (HER3) is a receptor tyrosine kinase that is expressed in numerous solid tumors. Higher levels of HER3 expression in multiple tumor types are associated with adverse clinical outcomes, such as reduced survival. However, there is currently no HER3-directed antibody-drug conjugate approved for the treatment of any cancer. Improved treatment options are needed, in particular for patients who progress on standard therapies. HER3-DXd is an investigational HER3-directed antibody-drug conjugate composed of an antiHER3 monoclonal antibody linked to a topoisomerase I inhibitor payload via a stable tetrapeptide-based cleavable linker. In previous clinical trials, HER3-DXd demonstrated a manageable safety profile and durable efficacy in previously treated, advanced EGFR-mutated NSCLC and advanced breast cancer across a range of baseline tumor HER3 expression levels. HER3-DXd has also shown preclinical antitumor efficacy in HER3-expressing cancers including cutaneous melanoma, gastric cancer, and prostate cancer, among others. The aim of this global phase II HERTHENA-PanTumor01 multicohort study is to assess the efficacy and safety of HER3-DXd in patients with relapsed or refractory locally advanced or metastatic solid tumors including melanoma, head and neck squamous cell, gastric/gastroesophageal junction, ovarian, cervical, endometrial, bladder, esophageal squamous cell, pancreatic, and prostate cancers.  \nClinical trial registration: NCT06172478 ([ClinicalTrials.gov](ClinicalTrials.gov)); 2023-507641-29-00 (EudraCT); jRCT2031230575 (Japan Registry of Clinical Trials) .  \nPLAIN LANGUAGE SUMMARY  \nEffective and","cbCaim3PZhyFXIPx","https://ap.wps.com/l/cbCaim3PZhyFXIPx","pdf",1184883,"English","# Abstract\n# Plain language summary\n# Article history\n# Keywords","[{\"question\":\"What is HER3-DXd and what is its mechanism of action?\",\"answer\":\"HER3-DXd is an investigational antibody-drug conjugate. It uses an anti-HER3 monoclonal antibody linked to a topoisomerase I inhibitor payload via a cleavable linker, releasing chemotherapy inside HER3-expressing cancer cells.\"},{\"question\":\"What patient populations and cancer types are included in HERTHENA-PanTumor01?\",\"answer\":\"The trial enrolls patients with relapsed or refractory locally advanced or metastatic solid tumors that are unresectable. Tumor types include melanoma, head and neck squamous cell carcinoma, gastric/gastroesophageal junction, ovarian, cervical, endometrial, bladder, esophageal squamous cell, pancreatic, and prostate cancers.\"},{\"question\":\"How is HERTHENA-PanTumor01 administered and what are the primary goals?\",\"answer\":\"Participants receive HER3-DXd every 3 weeks via IV infusion. The study aims to assess how well HER3-DXd shrinks tumors and to characterize side effects during treatment.\"}]","HERTHENA-PanTumor01 - Clinical trial protocol - phase II study of patritumab deruxtecan (HER3-DXd) | PDF",1790185377,25,[146,150,154,158],{"page_no":8,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/b0e7d3fcb7e28b5f062553904b0e6a79.webp",983,1280,{"page_no":14,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/1892cc32054a1f86e01e80941e715ef1.webp",982,1278,{"page_no":81,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/49ddfbeef051449d489af09c1a656a2a.webp",981,1277,{"page_no":19,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/7286fccb1b51f349b7778f6cbce3149e.webp",980,1276]